Pelthos Therapeutics Inc.
PTHS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 54.3% | – | – | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -191.9% | – | – | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -219.3% | – | – | – |
| EPS Diluted | -25.35 | -5.38 | -3.2 | -3.23 |
| % Growth | -371.2% | -68.1% | 0.9% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |